Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
Weide B, Garbe C, Rammensee HG, Pascolo S. Weide B, et al. Among authors: pascolo s. Immunol Lett. 2008 Jan 15;115(1):33-42. doi: 10.1016/j.imlet.2007.09.012. Epub 2007 Oct 26. Immunol Lett. 2008. PMID: 18006079 Review.
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.
Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Rittig SM, et al. Among authors: pascolo s. Mol Ther. 2011 May;19(5):990-9. doi: 10.1038/mt.2010.289. Epub 2010 Dec 28. Mol Ther. 2011. PMID: 21189474 Free PMC article. Clinical Trial.
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Widenmeyer M, et al. Among authors: pascolo s. Int J Cancer. 2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365. Epub 2011 Sep 14. Int J Cancer. 2012. PMID: 21858810 Clinical Trial.
68 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page